SCHEMBL492847

SCHEMBL492847

N#Cc1nc2ccc(OCc3cccnc3)cc2s1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSF1R P07333 3/20 0.60
F9 P00740 1/20 0.53
F10 P00742 1/20 0.53
CYP3A4 P08684 2/20 0.51
RAB9A P51151 2/20 0.51
CD274 Q9NZQ7 1/20 0.51
CA12 O43570 1/20 0.46
CA1 P00915 1/20 0.46
CA2 P00918 1/20 0.46
CA7 P43166 1/20 0.46
CA9 Q16790 1/20 0.46
MAPT P10636 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
NPC1 O15118 1/20 0.44
CYP11B1 P15538 1/20 0.44
MAPK1 P28482 3/20 0.43
PPARG P37231 1/20 0.43
NCOA2 Q15596 1/20 0.43
NCOA1 Q15788 1/20 0.43
NCOA3 Q9Y6Q9 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL492368 0.87 CYP3A4 (0.59) CSF1RCYP3A4RAB9ACA12CA1
SCHEMBL12336483 0.87 CYP3A4 (0.56) CSF1RCYP3A4RAB9ACA12CA1
SCHEMBL492622 0.87 CYP3A4 (0.66) CSF1RCYP3A4RAB9ACA12CA1
SCHEMBL12960182 0.81 CYP3A4 (0.51) CSF1RCYP3A4RAB9ACA12CA1
SCHEMBL12957921 0.81 CYP3A4 (0.51) CSF1RCYP3A4RAB9ACA12CA1
SCHEMBL906848 0.81 CYP3A4 (0.51) CSF1RCYP3A4RAB9ACA12CA1
SCHEMBL906628 0.81 CYP3A4 (0.61) CSF1RCYP3A4CA12CA1CA2
SCHEMBL12312849 0.80 CYP3A4 (0.60) CSF1RCYP3A4CA12CA1CA2
SCHEMBL12336473 0.80 CYP3A4 (0.60) CSF1RCYP3A4RAB9ACA12CA1
SCHEMBL12312848 0.80 CYP3A4 (0.60) CSF1RCYP3A4RAB9ACA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10408819-B2 Luminescence-based methods and probes for measuring cytochrome P450 activity PROMEGA CORPORATION (US) 2019-09-10 US disclosed
EP-2545041-B1 BIOLUMINESCENT ASSAYS USING CYANOBENZOTHIAZOLE COMPOUNDS PROMEGA CORP (US) 2017-08-02 EP disclosed
US-20170191985-A1 LUMINESCENCE-BASED METHODS AND PROBES FOR MEASURING CYTOCHROME P450 ACTIVITY JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT 2017-07-06 US disclosed
US-9574223-B2 Luminescence-based methods and probes for measuring cytochrome P450 activity PROMEGA CORPORATION (US) 2017-02-21 US disclosed
US-20140380514-A1 LUMINESCENCE-BASED METHODS AND PROBES FOR MEASURING CYTOCHROME P450 ACTIVITY JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT 2014-12-25 US disclosed
US-8765969-B2 Luminescence-based methods and probes for measuring cytochrome P450 activity PROMEGA CORPORATION (US) 2014-07-01 US disclosed
US-8106052-B2 Luminescence-based methods and probes for measuring cytochrome P450 activity PROMEGA CORPORATION (US) 2012-01-31 US disclosed
US-20110223625-A1 BIOLUMINESCENT ASSAYS USING CYANOBENZOTHIAZOLE COMPOUNDS PROMEGA CORPORATION (US) 2011-09-15 US disclosed
US-20110223625-A1 BIOLUMINESCENT ASSAYS USING CYANOBENZOTHIAZOLE COMPOUNDS PROMEGA CORPORATION (US) 2011-09-15 US disclosed
WO-2011112966-A1 BIOLUMINESCENT ASSAYS USING CYANOBENZOTHIAZOLE COMPOUNDS PROMEGA CORPORATION (US) 2011-09-15 WO disclosed
EP-1546162-B1 LUMINESCENCE-BASED METHODS AND PROBES FOR MEASURING CYTOCHROME P450 ACTIVITY PROMEGA CORP (US) 2011-06-22 EP disclosed
US-20110003316-A1 LUMINESCENCE-BASED METHODS AND PROBES FOR MEASURING CYTOCHROME P450 ACTIVITY PROMEGA CORPORATION (US) 2011-01-06 US disclosed
US-7692022-B2 Using luciferin derivatives for analyzing metabolic activity in animals, cells or in cell-free reaction formulations PROMEGA CORPORATION (US) 2010-04-06 US disclosed
US-20090023173-A1 Luminescence-based methods and probes for measuring cytochrome P450 activity PROMEGA CORPORATION (US) 2009-01-22 US disclosed
EP-1546162-A4 LUMINESCENCE-BASED METHODS AND PROBES FOR MEASURING CYTOCHROME P450 ACTIVITY PROMEGA CORP (US) 2007-07-18 EP disclosed
EP-1546162-A2 LUMINESCENCE-BASED METHODS AND PROBES FOR MEASURING CYTOCHROME P450 ACTIVITY PROMEGA CORPORATION (US) 2005-06-29 EP disclosed
US-20040171099-A1 Using luciferin derivatives for analyzing metabolic activity in animals, cells or in cell-free reaction formulations PROMEGA CORPORATION 2004-09-02 US disclosed
WO-2004027378-A2 LUMINESCENCE-BASED METHODS AND PROBES FOR MEASURING CYTOCHROME P450 ACTIVITY PROMEGA CORPORATION (US) 2004-04-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140380514-A1 LUMINESCENCE-BASED METHODS AND PROBES FOR MEASURING CYTOCHROME P450 ACTIVITY CYP3A43, CYP3A7, CYP3A5 CSF1R 4553/4885F9 4184/4885F10 2134/4885
US-20090023173-A1 Luminescence-based methods and probes for measuring cytochrome P450 activity CYP3A43, CYP3A7, CYP3A5 CSF1R 4553/4885F9 4184/4885F10 2134/4885
US-10408819-B2 Luminescence-based methods and probes for measuring cytochrome P450 activity CYP3A7, CYP3A43, CYP3A5 CSF1R 3751/4885F9 4110/4885F10 2696/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.